In August 2024, NICE prioritization board decisions were published regarding the following Med Tech-related topics: clinical guidelines on lower urinary tract symptoms in men (prioritized), NPi-200 for pupillary light reflex in critical care (not prioritized), Aquablation robotic therapy in benign prostatic hyperplasia (not prioritized), and tumor treating fields in glioblastoma (not prioritized).

In September 2024, the Finnish classification of procedures (THL) was updated two times. On September 6, 2024, seven new procedure codes concerning mental health and dental procedures were introduced. On September 11, 2024, forty new procedure codes concerning gastrointestinal, obstetrics and gynecology, surgical procedures, and some other fields were introduced. The codes will come into force on January 1, 2025.

On September 1, 2024, the application window opened to join the NHS Innovation Accelerator (NIA) program in 2025. NIA supports the development of individuals ('Fellows') and the spread of their innovation nationally. For the 2025 intake, the NIA seeks high-impact, evidence-based innovations that can address any challenge the healthcare system faces. The application deadline is October 14, 2024.

In September 2024, the Canary Islands Healthcare Evaluation Service (SESCS) is working on several HTAs, including evaluations in neuromodulation, IVD, and some other fields.

Molecular gene profile analysis (Oncotype DX) was evaluated within the "New Methods" framework starting in 2021. On August 26, 2024, the Decision Forum for "New Methods" recommended Oncotype DX to be introduced to predict the benefit of chemotherapy in postmenopausal patients with lymph node-positive, estrogen receptor-positive (ER+), human epidermal growth factor receptor-2 negative (HER2-) early-stage invasive breast cancer.

On July 31, 2024, NHS England and the National Institute for Health and Care Excellence (NICE) published a consultation document that proposes to increase the Budget Impact Test (BIT) threshold from £20 million to £40 million. The BIT applies during NICE's technology evaluation process. The deadline for comments submission is September 25, 2024.

On August 19, 2024, the Agenda for the meeting of the Board of Danish Regions was published. One of the themes to be discussed during the meeting was the Danish Regions consultation response regarding the Health Structure Commission's report. The meeting was held on August 22, 2024.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to better understand the potential scope of our support. From the week of the 9th of September, we are planning to work on 18 projects. Review the full list of planned activities in this post.

On July 25, 2024, the National Institute for Health and Care Research (NIHR) launched a funding call within the HTA Programme concerning ambitious data-enabled trial proposals (or “e-trials”). Proposed interventions need to be mature enough to be tested on a national scale. The application deadline is November 27, 2024.

In mid-August 2024, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions recommending the transfer to standard care for another four completed projects. The projects were dedicated to the topics of support for families with a parent suffering from cancer, modeling routine risk screening in children, reducing problematic media use, promoting treatment motivation in people with computer game addiction and Internet addiction, and follow-up care for gestational diabetes.

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in August 2024. Five recommendations were published concerning the registration of medical devices or modification of registration conditions/extension of indications for the medical devices in the List of Reimbursable Products and Services (LPPR). Opinions concern cardiovascular, peripheral vascular, neuromodulation, orthopedic, and spine devices.

NICE recently introduced a new centralized approach to prioritizing topics for its guidance and a decision-making body - a prioritization board. In July 2024, the decisions of the prioritization board were first published by NICE. Sixteen topics were prioritized, twenty were not prioritized, and one was withdrawn.